|Articles|June 22, 2009

FDA's Keith Webber on Setting Specifications

Author(s)BioPharm International Editors

FDA´s Keith Webber on Setting Specifications

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Related Content

T-Cells Work to Fight Cancer, Immunotherapy, CAR T-cell therapy, 3d rendering | Image credit: © Design Cells - © Design Cells - stock.adobe.com

New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline

ByFeliza Mirasol

December 5th 2025

Parkinson's disease. 3D illustration showing neurons containing Lewy bodies small red spheres which are deposits of proteins (alpha-synuclein) accumulated in the brain cells. | Image credit: © Lars Neumann - © Lars Neumann - stock.abode.com

Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies

ByFeliza Mirasol

December 4th 2025

small interfering RNA bound to a messenger RNA, cartoon model with semi-transparent surface. siRNAs are synthetic RNA interference tools used for inducing temporary reduction of mRNA expression. | Image credit: © petarg - © petarg - stock.adobe.com

Emerging siRNA Platform Offers New Metabolic Disorder Therapies

ByFeliza Mirasol

December 3rd 2025

Exosomes, cross section showing proteins and mRNA | Image credit: © Juan Gärtner - © Juan Gärtner - stock.adobe.com

How Engineered Exosomes Can Impact Targeted Therapies

ByFeliza Mirasol

December 3rd 2025

Creative image of embryonic stem cells, cellular therapy. 3d illustration | Image credit: © pinkeyes - © pinkeyes - stock.adobe.co

Implementing Automation and Flexible Design for Allogeneic Manufacturing

ByJennifer Markarian

December 2nd 2025

FDA's Keith Webber on Setting Specifications

Newsletter

Related Content

New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline

Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies

Emerging siRNA Platform Offers New Metabolic Disorder Therapies

How Engineered Exosomes Can Impact Targeted Therapies

Implementing Automation and Flexible Design for Allogeneic Manufacturing

Trending on BioPharm International

New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline

Emerging siRNA Platform Offers New Metabolic Disorder Therapies

Implementing Automation and Flexible Design for Allogeneic Manufacturing

Biocapacitance as a PAT Tool: Real-Time Biomass Monitoring for Upstream Bioprocessing

Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies